本誌28巻4号：257～268（2002）に掲載の竹尾智行氏論文「ハムスター膵・胆管合流胆道発癌モデルにおける化学予防の検討」において図に関して以下の部分を訂正し，お詫びいたします．

誤

Table 1. Pancreatic duct lesions

Group	Dose of chemopreventive agents	Effective no. of hamsters	Mean number of intrahepatic bile duct lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	3.83±1.19	1.92±1.93	0.33±0.65	6.08±3.15
etodolac	200 ppm	16	3.75±2.11	0.56±1.03 *	0 *	4.31±2.83
cimetidine	500 ppm	13	2.69±1.55	0.85±1.21	0.23±0.44	3.77±2.77
ranitidine	200 ppm	9	3.67±1.87	1.11±0.78	0.11±0.33	4.89±2.57
FOY-305	200 ppm	13	3.92±1.89	0.62±0.77 *	0.08±0.28	4.62±2.43
MGN-3	500 ppm	8	5.50±2.14	0.75±1.17	0.13±0.35	6.25±2.31

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of pancreatic ductal lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

Table 2. Extrahepatic bile duct lesions

Group	Dose of chemopreventive agents	Effective no. of hamsters	Mean number of gallbladder lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	0.92±1.51	1.08±0.79	0.25±0.62	2.25±0.96
etodolac	200 ppm	16	0.75±0.45	0.12±0.34 *	0	0.88±0.62 *
cimetidine	500 ppm	13	0.69±0.63	0.46±0.78	0.08±0.28	1.23±0.83 *
ranitidine	200 ppm	9	0.89±0.33	0.56±0.53	0	1.44±0.73
FOY-305	200 ppm	13	1.00±0.00	0.23±0.44 *	0	1.23±0.44 *
MGN-3	500 ppm	8	1.13±0.35	0.38±0.52	0	1.50±0.53

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of extrahepatic bile duct lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

Table 3. Intrahepatic bile duct lesions

Group	Dose of chemopreventive agents	Effective no. of hamsters	Mean number of pancreatic ductal lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	3.50±1.45	2.08±2.11	1.25±1.48	6.83±3.04
etodolac	200 ppm	16	2.81±1.51	1.13±1.20	0.31±0.48 *	4.25±2.32 *
cimetidine	500 ppm	13	1.54±1.27 *	1.61±1.19	0.69±0.75	3.85±2.44 *
ranitidine	200 ppm	9	2.11±0.93 *	1.33±0.87	0.67±0.71	4.11±2.03 *
FOY-305	200 ppm	13	2.08±1.41 *	1.23±1.09	0.54±0.66	3.85±1.99 *
MGN-3	500 ppm	8	3.88±1.81	1.38±1.77	0.63±0.74	5.75±3.77

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of intrahepatic bile duct lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

Table 4. Gallbladder lesions

Group	Dose of Chemopreventive agents	Effective no. of hamsters	Mean number of extrahepatic bile duct lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	1.25±0.97	1.58±1.93	0.08±0.29	2.92±1.56
etodolac	200 ppm	16	1.88±0.95	0.19±0.83 *	0	2.06±0.85
cimetidine	500 ppm	13	0.85±0.99	0.08±0.28 *	0	0.92±0.95 *
ranitidine	200 ppm	9	1.22±0.67	0.78±0.44	0	2.00±1.00
FOY-305	200 ppm	13	1.46±0.78	0.23±0.60 *	0	1.69±0.85 *
MGN-3	500 ppm	8	1.88±0.84	0.25±0.46	0	2.13±0.83

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of gallbladder lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

正

Table 1. Pancreatic duct lesions

Group	Dose of chemopreventive agents	Effective no. of hamsters	Mean number of pancreatic ductal lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	3.50±1.45	2.08±2.11	1.25±1.48	6.83±3.04
etodolac	200 ppm	16	2.81±1.51	1.13±1.20	0.31±0.48 *	4.25±2.32 *
cimetidine	500 ppm	13	1.54±1.27 *	1.61±1.19	0.69±0.75	3.85±2.44 *
ranitidine	200 ppm	9	2.11±0.93 *	1.33±0.87	0.67±0.71	4.11±2.03 *
FOY-305	200 ppm	13	2.08±1.41 *	1.23±1.09	0.54±0.66	3.85±1.99 *
MGN-3	500 ppm	8	3.88±1.81	1.38±1.77	0.63±0.74	5.75±3.77

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of intrahepatic bile duct lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

Table 2. Extrahepatic bile duct lesions

Group	Dose of Chemopreventive agents	Effective no. of hamsters	Mean number of extrahepatic bile duct lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	1.25±0.97	1.58±1.93	0.08±0.29	2.92±1.56
etodolac	200 ppm	16	1.88±0.95	0.19±0.83 *	0	2.06±0.85
cimetidine	500 ppm	13	0.85±0.99	0.08±0.28 *	0	0.92±0.95 *
ranitidine	200 ppm	9	1.22±0.67	0.78±0.44	0	2.00±1.00
FOY-305	200 ppm	13	1.46±0.78	0.23±0.60 *	0	1.69±0.85 *
MGN-3	500 ppm	8	1.88±0.84	0.25±0.46	0	2.13±0.83

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of gallbladder lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

Table 3. Intrahepatic bile duct lesions

Group	Dose of chemopreventive agents	Effective no. of hamsters	Mean number of intrahepatic bile duct lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	3.83±1.19	1.92±1.93	0.33±0.65	6.08±3.15
etodolac	200 ppm	16	3.75±2.11	0.56±1.03 *	0 *	4.31±2.83
cimetidine	500 ppm	13	2.69±1.55	0.85±1.21	0.23±0.44	3.77±2.77
ranitidine	200 ppm	9	3.67±1.87	1.11±0.78	0.11±0.33	4.89±2.57
FOY-305	200 ppm	13	3.92±1.89	0.62±0.77 *	0.08±0.28	4.62±2.43
MGN-3	500 ppm	8	5.50±2.14	0.75±1.17	0.13±0.35	6.25±2.31

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of pancreatic ductal lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct

Table 4. Gallbladder lesions

Group	Dose of chemopreventive agents	Effective no. of hamsters	Mean number of gallbladder lesions (mean±SD)			
			Hyperplasia	Atypical hyperplasia	Carcinoma	Total
no therapy	0	12	0.92±1.51	1.08±0.79	0.25±0.62	2.25±0.96
etodolac	200 ppm	16	0.75±0.45	0.12±0.34 *	0	0.88±0.62 *
cimetidine	500 ppm	13	0.69±0.63	0.46±0.78	0.08±0.28	1.23±0.83 *
ranitidine	200 ppm	9	0.89±0.33	0.56±0.53	0	1.44±0.73
FOY-305	200 ppm	13	1.00±0.00	0.23±0.44 *	0	1.23±0.44 *
MGN-3	500 ppm	8	1.13±0.35	0.38±0.52	0	1.50±0.53

*Significant difference from no therapy ($p<0.05$)

Effects of chemopreventive agents on the development of extrahepatic bile duct lesions induced in hamsters by cholecystoduodenostomy with dissection of the common bile duct